Kwaliteitscontrole ...................................................................................................... 44
Beperkingen ............................................................................................................. 44
Prestatiekenmerken ................................................................................................... 47
Klinische prestaties ......................................................................................... 47
Analyseprestaties ............................................................................................ 51
Bijlage B: Woordenlijst .............................................................................................. 79
Referenties ............................................................................................................... 81
Symbolen................................................................................................................. 82
Gebruiksaanwijzing (Handleiding) van QIAstat-Dx Meningitis/Encephalitis (ME) Panel 09/2022
3